“We believe the Allurion Program is the only solution for obesity management that has consistently demonstrated significant and immediate weight loss while maintaining or increasing muscle mass,” said Shantanu Gaur, founder and CEO of Allurion. “In combination with low-dose GLP-1s, we believe the clinical benefit increases even more given the higher adherence levels for GLP-1s, and we are confident that, by pivoting to this approach, we will capitalize on the success of GLP-1s and set Allurion up for long-term success.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALUR:
- Allurion Technologies Announces Strategic Restructuring Plan
- Allurion announces new strategic direction, focuses on GL-P1 combo therapy
- Allurion publishes long-term weight loss results with Allurion Program
- Allurion Technologies announces distribution partnership with Minogue
- Allurion Technologies submits PMA to FDA, announces additional AUDACITY data